Nuvig halts development of lead drug for rare autoimmune disease
Nuvig Therapeutics halted development of its lead drug for a rare autoimmune disease.
Nuvig Therapeutics
Private
Biotechnology company developing therapies that restore immune homeostasis for chronic inflammatory and autoimmune diseases.
Company Info
Sector:Biologics / Autoimmune
Headquarters:Menlo Park, California, United States
Founded:2022
Website:nuvigtx.com/
Total Funding:$208M
Funding & Investor Relations
Notable Investors
- Norwest Venture Partners
- Sanofi Ventures
IPO Outlook / Plans
Private; no IPO announced